Thermo Fisher Scientific Continues Collaboration with Symphogen
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Thermo Fisher Scientific Continues Collaboration with Symphogen

By Pharma Tech Outlook | Monday, November 09, 2020

Thermo Fisher Scientific has announced the extension of a strategic collaboration to offer an industry-proven simple analysis of complex therapeutic proteins to enhance biopharmaceutical discovery and development.

FREMONT, CA: Thermo Fisher Scientific, a leader in serving science, and Symphogen, an associate and antibody center of excellence within the international pharmaceutical organizations, have announced the extension of strategic collaboration. It will offer industry-proven, advanced characterization, and quality control workflows to simplify complex therapeutic proteins to improve biopharmaceutical discovery and development.

Since the partnership was established in 2018, Symphogen uses the Thermo Scientific Q Exactive Plus Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) system BioPharma Option, and most recently, the Thermo Scientific Orbitrap Exploris 480 mass spectrometer. It is being used to develop, test, and routinely implement the platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures. The high-performance, easy-to-use, analytical workflows were developed to allow dynamic biopharmaceutical companies, such as Symphogen, to deliver accurate treatment choices for patients.

"Through our collaboration with Symphogen, we can provide the biopharmaceutical industry with proven characterization methods that can be translated into transferable, routine, compliance-ready solutions to boost drug discovery and development," said Eric Grumbach, director, biopharma/pharma, chromatography and mass spectrometry, Thermo Fisher Scientific. "By continuing to invest in this relationship, we demonstrate our commitment to offer solutions designed to tackle today's most pressing biopharmaceutical challenges."

Dan Bach Kristensen, principal investigator, Symphogen, said, "Over the past two years, the advanced characterization and lead selection studies of several hundred mAb samples enabled by the Q Exactive Plus Orbitrap LC-MS/MS system has allowed us to simplify our analytical strategies, ultimately accelerating our pipeline. Extending our collaboration with Thermo Fisher is the natural way forward to continue driving innovation in the discovery and development of highly differentiated cancer therapeutics."

Along with the Q Exactive Plus Orbitrap and Exploris 480 LC-MS/MS systems, Symphogen even utilizes the Thermo Scientific Orbitrap Fusion Tribrid mass spectrometer. The organization's Thermo Fisher mass spectrometry analyzers' network is accomplished with the help of Thermo Scientific Vanquish ultra-high-performance liquid chromatography (UHPLC) systems and Thermo Scientific Chromeleon Chromatography Data System (CDS) software, which is being used by Symphogen for more than a decade.

Weekly Brief

Read Also